Lavipharm S.A. Share Price

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. 07:40:04 17/09/2026 pm IST			5-day change	1st Jan Change
1.610 ^EUR	+1.26%		+1.26%	+65.98%

25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
28/05	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE

Lavipharm SA is a Greece-based pharmaceutical and healthcare company engaged in the research and development of drug delivery solutions and the commercialisation of pharmaceutical, over-the-counter (OTC) and related healthcare products. It is active in the provision of prescription medicines, OTC products and food supplements, supported by integrated activities across research and development, manufacturing and commercial operations. It maintains a portfolio focused primarily on therapeutic areas including cardiology, central nervous system disorders, urology, oncology and chronic pain, supplying solutions designed for healthcare professionals and patients. The Company operates in both domestic and international markets and combines product development capabilities with market access and distribution activities, while acting as the parent entity of the Lavipharm Group through which its broader operations are conducted.

Employees

285

Sector

Pharmaceuticals

Calendar

07:50pm Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
17/26/17	€1.610	+1.26%	97,120
16/26/16	€1.590	+0.63%	1,16,996
15/26/15	€1.580	+2.07%	1,81,580
14/26/14	€1.548	-1.28%	1,67,207
11/26/11	€1.568	-1.38%	24,032

Delayed Quote Athens S.E.

More quotes

Market Cap	27Cr 32Cr 26Cr 24Cr 44Cr 3.02TCr 44Cr 309.95Cr 119.85Cr 1.54TCr 118.59Cr 115.95Cr 4.92TCr	P/E 2024	14.9x	P/E 2025	27.9x
Enterprise Value	30Cr 35Cr 29Cr 26Cr 48Cr 3.32TCr 49Cr 340.02Cr 131.48Cr 1.69TCr 130.09Cr 127.2Cr 5.4TCr	EV / Sales 2024	3.07x	EV / Sales 2025	3.04x
Free-Float	39.31%	Yield 2024	2.52%	Yield 2025	-

25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
28/05	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE
28/05	Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
09/04	Lavipharm to acquire Durogesic pain patch rights from Janssen for $12.0 million	RE
19/03	Lavipharm SA FY 2025 earnings after tax EUR 6.0 million versus EUR 9.0 million year ago	RE
19/03	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
17/11	Lavipharm 9-month net profit down to EUR 3.5 million	RE
18/25/18	Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y	RE
18/25/18	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/25/03	Lavipharm S.A. announces Annual dividend, payable on July 24, 2025	CI
15/25/15	Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY	RE
14/25/14	Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company	RE
19/25/19	Lavipharm FY 2024 Earnings After Tax EUR 9.0 Million Versus EUR 1.87 Million Year Ago	RE

03/09	Lavipharm S A : Announcement Appointment of Chief Manufacturing & Operations Officer	PU
11/06	Lavipharm S A : Announcement Appointment of Chief Quality Officer	PU
22/05	Lavipharm S A : IMPORTANT CORPORATE EVENTS	PU
07/11	Lavipharm S A : OTHER ANNOUNCEMENTS	PU
15/25/15	Lavipharm S A : ANNOUNCEMENT OF REGULATED INFORMATION - TRANSACTIONS NOTIFICATION	PU

1 day	+1.26%
1 week	+1.26%
Current month	-2.31%
1 month	+2.94%
3 months	+4.95%
6 months	+31.32%
Current year	+65.98%

1 week	1.53	1.61
1 month	1.53	1.69
Current year	0.94	1.74
1 year	0.76	1.74
3 years	0.58	1.74
5 years	0.35	2.22
10 years	0.16	2.22

Lavipharm S.A. Share Price

Stocks

LAVI

GRS246003008

Pharmaceuticals

Valuation: Lavipharm S.A.

Chart: Lavipharm S.A.

Latest news: Lavipharm S.A.

Press Releases: Lavipharm S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Lavipharm S.A.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Vassilis Baloumis DFI	Director of Finance/CFO	-	01/12/2021
Ligia Panaitescu CTO	Chief Tech/Sci/R&D Officer	-	-
Eleana Nikolopoulou CMP	Compliance Officer	-	-

Director	Title	Age	Since
Venetsiana-Loukia Lavida BRD	Director/Board Member	-	-
Christos Panagiotis Diamantopoulos BRD	Director/Board Member	76	-
Minas G. Tanes CHM	Chairman	86	01/01/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/25	Vassilis Baloumis	Buy	Chief Financial Officer	20,000	0.0119%
27/05/23	Thomas Tseronis	Sell		35,434	0.0189%
28/03/23	Vassilis Baloumis	Buy	Chief Financial Officer	23,455	0.0125%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVIPHARM S.A.	+1.26%	+1.26%	+82.95%	+134.01%	31Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.74%	+0.13%	+15.95%	+62.40%	4.64TCr
OTSUKA HOLDINGS CO., LTD.	+3.03%	-3.77%	+32.57%	+102.58%	3.69TCr
ZYDUS LIFESCIENCES LIMITED	+2.49%	+0.68%	+9.72%	+75.89%	1.15TCr
CIPLA LIMITED	+1.35%	+0.97%	-11.72%	+11.40%	1.14TCr
KRKA, D. D.	+0.19%	+0.77%	+19.55%	+149.29%	917.11Cr
GEDEON RICHTER	+1.43%	+2.32%	+29.48%	+38.09%	727.44Cr
ONO PHARMACEUTICAL CO., LTD.	+2.60%	+1.59%	+37.15%	-18.62%	705.95Cr
GLENMARK PHARMACEUTICALS LIMITED	+0.25%	-0.78%	+16.32%	+182.08%	708.94Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+1.38%	-4.13%	-42.75%	+6.68%	492.05Cr
Average	+1.47%	-1.01%	+18.92%	+74.38%	1.42TCr
Weighted average by Cap.	+1.62%	-2.09%	+17.65%	+74.37%

	2024	2025
Net sales	5.29Cr 6.08Cr 5.01Cr 4.55Cr 8.51Cr 582.17Cr 8.55Cr 60Cr 23Cr 295.86Cr 23Cr 22Cr 947.13Cr	6.26Cr 7.19Cr 5.92Cr 5.38Cr 10Cr 688.15Cr 10Cr 71Cr 27Cr 349.72Cr 27Cr 26Cr 1.12TCr
Net income	89.82L 1.03Cr 85.01L 77.24L 1.44Cr 99Cr 1.45Cr 10Cr 3.92Cr 50Cr 3.87Cr 3.79Cr 160.68Cr	59.86L 68.73L 56.65L 51.47L 96.16L 66Cr 96.64L 6.75Cr 2.61Cr 33Cr 2.58Cr 2.52Cr 107.08Cr
Net Debt	2.83Cr 3.25Cr 2.68Cr 2.44Cr 4.55Cr 311.56Cr 4.57Cr 32Cr 12Cr 158.34Cr 12Cr 12Cr 506.87Cr	2.67Cr 3.06Cr 2.52Cr 2.29Cr 4.28Cr 293.28Cr 4.31Cr 30Cr 12Cr 149.05Cr 12Cr 11Cr 477.14Cr